Immunotherapy in nonmelanoma skin cancer.
Nonmelanoma skin cancer is the most common type of cancer in humans. The role of the immune system in the prevention and regression of cancer is significant. UV radiation, being the most important risk factor in the development of skin cancer, has a suppressive effect on local and systemic immune effectors. Different immunotherapeutic approaches have been used for the treatment of nonmelanoma skin cancer including adoptive T-cell therapies, vaccine-based strategies, cytokines and monoclonal antibodies. The most important advancement with promising effects in the field of nonmelanoma skin cancer immunotherapy is the topical immune response modifier imiquimod. In addition, immunoprevention has been successfully applied for autosomal dominant basal cell nevus syndrome. Immunotherapeutic approaches provide a new modality for the treatment of recurrent or multiple nonmelanoma skin tumors.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran. ghafourifard@razi.tums.ac.ir
Soudeh
S
Ghafouri-Fard
Somayyeh
S
Ghafouri-Fard
D000634:Aminoquinolines / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
D000634:Aminoquinolines; D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D016207:Cytokines; D007155:Immunologic Factors; D000077271:Imiquimod